Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377750 | 0.92 | TSHR (0.47) | TSHRUSP2CA1CA2POLB | |
| Silver SCHEMBL16701109 | 0.92 | — | — | |
| SCHEMBL16680971 | 0.92 | TSHR (0.47) | TSHRUSP2CA1CA2POLB | |
| SCHEMBL16700173 | 0.92 | — | — | |
| SCHEMBL29529996 | 0.92 | TSHR (0.47) | TSHRUSP2CA1CA2POLB | |
| SCHEMBL60049 | 0.92 | — | — | |
| SCHEMBL925566 | 0.92 | — | — | |
| SCHEMBL3235514 | 0.92 | TSHR (0.47) | TSHRUSP2CA1CA2POLB | |
| Lithium Ion SCHEMBL1034873 | 0.92 | — | — | |
| SCHEMBL29377219 | 0.92 | TSHR (0.47) | TSHRUSP2CA1CA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161365-A1 | Phosphate-Binding Magnesium Salts And Uses Thereof | CURRAX PHARMACEUTICALS LLC | 2018-06-14 | — | — | US | claimed |
| US-9889157-B2 | Phosphate-binding magnesium salts and uses thereof | CYPRESS PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | claimed |
| US-20170202875-A1 | Phosphate-Binding Magnesium Salts And Uses Thereof | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2017-07-20 | — | — | US | claimed |
| US-9610267-B2 | Phosphate-binding magnesium salts and uses thereof | CYPRESS PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | claimed |
| US-20160256420-A1 | Phosphate-Binding Magnesium Salts And Uses Thereof | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2016-09-08 | — | — | US | claimed |
| US-9339481-B2 | Phosphate-binding magnesium salts and uses thereof | CYPRESS PHARMACEUTICALS, INC. (US) | 2016-05-17 | — | — | US | claimed |
| EP-2416786-A1 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF | Cypress Pharmaceutical, Inc. (US) | 2012-02-15 | — | — | EP | claimed |
| WO-2010117370-A1 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF | CYPRESS PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | claimed |
| US-20090269399-A1 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF | CYPRESS PHARMACEUTICAL, INC. (US) | 2009-10-29 | — | — | US | claimed |
| US-20240284941-A1 | ANTIHISTAMINES COMBINED WITH DIETARY SUPPLEMENTS FOR IMPROVED HEALTH | REQUIS PHARMACEUTICALS INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-11850231-B1 | Trytophan metabolic stimulation compositions | COOK CHRISTINA RAHM (US) | 2023-12-26 | — | — | US | disclosed |
| WO-2023238500-A1 | TREATMENT AGENT FOR CARBON FIBER PRECURSOR, AND CARBON FIBER PRECURSOR | 竹本油脂株式会社 | 2023-12-14 | — | — | WO | disclosed |
| CN-115353466-A | Preparation and purification method of neostigmine methosulfate | 云南先施药业有限公司 | 2022-11-18 | — | — | CN | disclosed |
| EP-3612515-B1 | PROCESS FOR PURIFYING ALKANESULFONIC ANHYDRIDE AND PROCESS FOR PRODUCING ALKANESULFONIC ACID USING THE PURIFIED ALKANESULFONIC ANHYDRIDE | BASF SE (DE) | 2022-07-20 | — | — | EP | disclosed |
| US-4058391-A | 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1977-11-15 | — | — | US | disclosed |
| US-4041046-A | INTERMEDIATES FOR THE CORRESPONDING HERBICIDAL PYRAZOLIUM SALTS ON | AMERICAN CYANAMID COMPANY (US) | 1977-08-09 | — | — | US | disclosed |
| US-4009277-A | 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as fungicidal agents | AMERICAN CYANAMID COMPANY (US) | 1977-02-22 | — | — | US | disclosed |
| US-4003732-A | Pyrazolinium compounds as herbicides | AMERICAN CYANAMID COMPANY (US) | 1977-01-18 | — | — | US | disclosed |
| US-3963742-A | 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1976-06-15 | — | — | US | disclosed |
| US-3947583-A | Method for controlling fungi utilizing pyrazolinium compounds | AMERICAN CYANAMID COMPANY (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240284941-A1 | ANTIHISTAMINES COMBINED WITH DIETARY SUPPLEMENTS FOR IMPROVED HEALTH | TPH1, TPH2, HRH3 | TSHR 1648/4885USP2 2196/4885CA1 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.